Scott H. Kaufmann

Scott H. Kaufmann, M.D., Ph.D., is a Professor of Medicine and Pharmacology at Mayo Clinic, where he serves as the Leader of the Novel Therapeutics and Therapeutic Modalities Program at the Mayo Clinic Comprehensive Cancer Center. His academic roles include appointments in the Department of Oncology, Division of Hematology, and Department of Molecular Pharmacology and Experimental Therapeutics.

• Primary Affiliation: Mayo Clinic College of Medicine and Science
• Key Roles: Consultant in Oncology Research, Principal Investigator of multiple grants, and Director of the Anticancer Drug Action Laboratory

Education: Johns Hopkins University School of Medicine (MD, PhD in Pharmacology), Carleton College (BA in Chemistry).

Research focuses on apoptosis mechanisms, targeted anticancer therapies, and PARP inhibitors in ovarian cancer. Key areas include drug resistance, mitochondrial apoptosis pathways, and translational studies linking lab findings to clinical trials like the ARIEL2 trial for rucaparib.

Grants and Awards: Recipient of the Helen C. Levitt Professorship, Eric and Wendy Schmidt Fund for AI Research, and leadership of major projects such as the Ovarian Cancer SPORE and Next Generation TOP1 Inhibition studies.

Clinical Trials: Developed treatments combining PARP inhibitors with other agents for platinum-resistant cancers and myeloid neoplasms. Active in designing trials for mantle cell lymphoma and acute myeloid leukemia.